Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary
November 8, 2022
Earnings Call Speaker Segments
David Szekeres
executiveDennis, thanks. Hello, everyone, and I appreciate you being with us this afternoon. Joining me from Heron are Barry Quart, our Chief Executive Officer and Chairman; John Poyhonen, President and Chief Commercial Officer; and Kimberly Manhard, Executive Vice President of Drug Development and Board Director. If you're on the conference call, the slides are available through webcast, and you can also get them by visiting the Investor Relations page on our website once today's call wraps up. Prior to starting, please note that forward-looking statements regarding Heron's future expectations, plans, prospects, corporate strategy and performance will be part of this call, and these qualify as forward-looking statements under the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Various important factors, including those covered in our SEC filings, could cause actual results to differ materially from what these forward-looking statements indicate. Furthermore, any forward-looking statements reflect our views only as of today's webcast date and shouldn't be relied upon as representing our views as of any later date. We expressly disclaim any obligation to update such statements. I'll now hand the call over to Barry.
Barry Quart
executiveThanks, David. Hello, everybody, and I appreciate you being with us. On several fronts, the third quarter proved productive, while in other areas it fell short of what we wanted. Obviously, we're thrilled that APONVIE won approval — that's our fourth product to reach the commercial stage. The indication for APONVIE is preventing postoperative nausea and vomiting, which we call PONV, in adults. Come the first quarter, APONVIE will hit the market as a highly convenient, room-temperature-stable, ready-to-use 32 milligram single-dose vial, given directly as a 30 second intravenous injection before anesthesia induction. For PONV, it will stand as the sole intravenous NK1 receptor antagonist on the market. During our September NDA approval call, as we explained then, the approval of APONVIE rested on findings from 2 randomized controlled trials testing aprepitant versus the standard of care, ondansetron, among patients who had open abdominal surgery. Across both trials, patients on ondansetron for prophylaxis vomited through 48 hours after surgery at more than double the rate of those given aprepitant. Our strong conviction is that APONVIE will mirror CINVANTI, rapidly turning into a key product for clinicians and patients alike. John will walk through the commercial opportunity and how we're pricing it. John will discuss our CINV franchise as well, which continues to expand even with generic rivals and is on track to reach between $93 million and $95 million in net product sales for the year. Where we have not met expectations is with the ZYNRELEF launch. Our third quarter performance is disappointing to us. A unit increase of 18% from the prior quarter isn't good enough; we understand that, and we're pursuing every avenue to alter the launch's course. You'll hear about encouraging strides in getting IDNs to swap ZYNRELEF in place of Exparel. We've borrowed a strategy from the Exparel rollout and started efforts to bring additional field staff on board via contractual arrangements, which John will touch on briefly, with further details coming during upcoming calls. Luckily, once elective procedures started climbing in October and the first phases of our fresh approaches began to show results, we achieved our strongest month to date, and everything indicates a stronger fourth quarter. Back in December, we secured a better indication statement for ZYNRELEF without any additional data, spanning 7 million procedures. We likewise finalized a written arrangement with the FDA regarding which additional data would be required for a full label spanning the 14 million soft tissue and orthopedic procedures we had initially set our sights on. The studies we agreed to have now been finished, and we are heavily engaged in putting together what we refer to as sNDA #2, which is intended to secure the broader indication; submission of this NDA is slated for late this year. Keep in mind that safety and pharmacokinetics served as the primary endpoints for those studies. It's my pleasure to share that we saw no novel safety concerns, and bupivacaine PK remained consistent after ZYNRELEF was given in these extra procedures. This slide shows that when you normalize for dose, bupivacaine's Cmax with ZYNRELEF tends to stay steady and comes in below that of bupivacaine HCL. Our view is that these findings will serve as the groundwork for broader indications in the coming year, which would remove a significant headwind for ZYNRELEF. At this point I'll hand the call over to John.
John Poyhonen
executiveThanks, Barry. Our acute care and oncology care franchises keep moving forward. In my presentation, I'll begin with several updates on key performance metrics for ZYNRELEF, after which I'll give an update regarding our PONV pricing strategy, and I'll wrap up with an update on yet another solid commercial quarter for our oncology care business. Let me begin by recapping ZYNRELEF's quarterly results on our leading indicators. Even though third quarter results took a hit from a decrease in indicated surgical procedures, which I'll cover on the following slide, ZYNRELEF net sales climbed to $2.7 million for the quarter, an 8% rise compared with the prior quarter. Demand units in the third quarter rose to 15,077 units, an 18% gain versus the prior quarter; this expansion was affected by a July that came in much slower than anticipated. The gap between the 8% net sales gain and the 18% unit demand gain came from a lower ZYNRELEF net price, mainly the result of higher 340B sales plus a larger share of 200 milligram SKUs being purchased to support the momentum ZYNRELEF is building in general surgery and foot and ankle procedures. Total ZYNRELEF unique ordering accounts climbed to 704, while the account reorder rate stayed strong at 84%. Total formulary approvals for ZYNRELEF rose to 416 approvals. Importantly, we're seeing growth with integrated delivery networks, or IDNs, with 66 IDNs having added ZYNRELEF to formulary. Securing IDN support matters a great deal for driving therapeutic interchanges with key accounts that substitute ZYNRELEF for Exparel in our indicated procedures going forward. On the whole, while we definitely made progress during Q3, we know we can do better. And we have refocused our Q4 priorities to speed up ZYNRELEF sales within our existing user accounts. As I noted on the previous slide, we believe third quarter results were affected by a decrease in indicated procedures. This line chart displays the volume of currently indicated procedures since 2019. Several observations are relevant. First, our target indicated procedures still haven't come back to 2019 levels. Second, the July to August stretch in 2022 had the lowest volume across the 4 years measured. And finally, the first 10 weeks of Q3 fell 11% compared with the first 10 weeks in Q2. While the market — despite the market's weakness, ZYNRELEF expanded 18% in Q3, and the brand keeps making steady progress. By comparison, Symphony data shows that in the third quarter 2022, Exparel total unit demand volume fell by 3% versus the prior quarter. As mentioned earlier, ZYNRELEF demand unit volume rose by 18% in the third quarter over the second quarter; that works out to an average of 1,160 units per week during the quarter. We're entering Q4 with some encouraging news. October became our highest volume month ever at 6,534 units. That works out to 1,475 units per week, a 27% gain over the Q3 weekly average. Traditionally, elective surgical procedures have peaked during Q4, and the beginning of this quarter has given us reasons for optimism. Given that expansion, we expect ZYNRELEF net product sales to rise somewhere between 30% and 40% during the fourth quarter versus the quarter before it. By the close of October, ZYNRELEF formulary approvals had climbed to 416 in total. Among those accounts that genuinely make P&T decisions, more than 90% of hospital P&T committees keep adding ZYNRELEF to the formulary. Notably, roughly 68% of the approvals we have for our formulary cover unrestricted use of ZYNRELEF. Deploying more resources toward accounts that already use the product, so as to drive pull-through in Q4, ranks among the key strategic changes we are implementing. Beyond that, we are concentrating on broadening the surgeons and procedures for which ZYNRELEF is appropriate, particularly within IDNs, to speed up ZYNRELEF volume and net sales. We recognize that fresh formulary approvals assist us in building an essential pipeline for new ZYNRELEF business, yet generating heavier usage within our current ordering accounts remains the commercial team's foremost priority. Now, I'd like to give an update on the central top-down strategy of aiming at integrated delivery networks to open new system-wide possibilities for therapeutic interchange from Exparel to ZYNRELEF for indicated procedures. So far, 66 IDNs have placed ZYNRELEF on their formularies, and 35% of those approvals permit unrestricted use of ZYNRELEF. More than 1 million annual ZYNRELEF-indicated procedures are accounted for by these 66 IDNs. Lastly, our IDN formulary expansion now spans $143 million in annual Exparel sales; at present we have 15 IDNs at differing stages of assessing a switch from Exparel to ZYNRELEF for indicated procedures; let's now examine the 15 IDNs interested in possible therapeutic interchange. Given ZYNRELEF's existing expanded label indications, it comes as no surprise that IDNs seek to save millions of dollars with a product that has shown superior clinical results versus the standard of care in head-to-head trials; we're delighted to partner with both pharmacy and physicians to advance their internal evaluations with ZYNRELEF. Out of the 15 IDNs moving ahead, every one of the 15 has started its internal trials. Feedback from their trials remains highly positive across a range of surgical procedures. Although shifting a large IDN definitely requires time, 5 IDNs have by now reached positive decisions for therapeutic interchange and are currently switching to ZYNRELEF for indicated procedures. During the previous quarter, we rolled out a new metric to help us assess the impact we are having with IDNs. As a reminder, branded market share is the new metric for measuring performance, and it is simply ZYNRELEF units divided by the total number of Exparel units plus ZYNRELEF units. On the whole, across the 66 IDNs holding formulary approval, we have shown solid growth in branded market share. One thing to bear in mind is that when we bring new IDNs on board, our share actually goes down, since we're developing fresh business within those accounts. Take last quarter, for instance: we had 57 IDNs with formulary approvals, and that figure has since risen to 66. Moving IDNs toward therapeutic interchange evaluation matters a great deal when it comes to speeding up ZYNRELEF's growth. The table makes clear that the 15 IDNs assessing TI hold a combined 12.4 branded market share in Q3 — more than 50% above the average seen across the 66 IDNs that have ZYNRELEF on formulary. We've also included ZYNRELEF's branded unit market share for the top 5 IDN share accounts among those 15 IDNs assessing TI. That table shows our branded market share is capable of rising quite rapidly, exceeding 50% for Q3. Given the procedures currently indicated, 50% market share is nearing the ceiling until an additional label expansion arrives, which we expect in the second half of 2023; versions of this slide have been shown before. My focus today will be purchase price, cost savings and reimbursement benefits. Moving to ZYNRELEF yields a cost savings of 25% to 32%, calculated on wholesale acquisition cost. During the fourth quarter, Pacira put in place an estimated 25% discount off WACC pricing, and for the first time is providing 340B pricing for Exparel. Despite Pacira's 340B pricing, ZYNRELEF continues to deliver 340B accounts savings of 23% to 31% when measured against Exparel.
John Poyhonen
executiveA lot of the 340B customers we've talked to have told us that when it comes to the ZYNRELEF pricing strategy, Pacira's reaction came too late and was too small. It's curious that Pacira made this move so late in the product life cycle, given how much of a financial hit their business will take. According to Symphony data, 340B-eligible accounts make up 45% of Exparel's hospital sales, so a 23% discount might substantially cut into top line sales and profits. If they hadn't started to see us gaining traction in 340B accounts and growing into a bigger threat, we doubt they would have absorbed this blow. Last, when you look at reimbursement, ZYNRELEF is still far more profitable with Medicare patients in the hospital outpatient and ASC settings of care. Amid these tough financial times, 340B accounts still see a financial gain of more than $340 per patient when they choose ZYNRELEF over Exparel. Given these economic advantages, it comes as no surprise that large IDNs keep evaluating ZYNRELEF for TI in indicated procedures and are eager to restrict Exparel's usage. I'll wrap up the ZYNRELEF section with our refocused priorities for 2022. Building consistent usage in ordering accounts sits at the top of our list. Close to 600 accounts have reordered, and we're focused on boosting pull-through and growing average order size. We'll get there by adding more surgeons who use ZYNRELEF at each account and more surgical procedures in which it's used. In October, we started deploying new flexible resources so we'd have extra personnel to in-service surgeons and their staff. Put simply, we want the right resources at the right account at the right time. These new resources matter especially in formulary approved IDNs with multiple hospitals in a given geography, where there can be too many accounts to cover all at once. These contracted resources give us the bandwidth to grow faster. Another plus is our ability to deploy resources in territories quickly and cost effectively. We're already starting to see the initial impact of these new resources and expect the true impact to show up in Q1. Maximizing our separate reimbursement outside the surgical bundle payment for ZYNRELEF is our second priority. The CMS pass-through status ZYNRELEF holds for Medicare patients in the hospital outpatient setting of care keeps making a positive impact, particularly in IDNs. On top of that, ZYNRELEF now has approval for separate reimbursement across over 200 million covered lives from commercial payers and Medicaid. Last, we'll keep securing formulary approvals at new targeted IDNs and hospitals to build our pipeline for growth and therapeutic interchange opportunities. I'll now move the presentation to APONVIE, our new product for the prevention of postoperative nausea and vomiting, or PONV. In my September approval presentation, I focused on the market opportunity. Today, I'll share specific details about our pricing strategy for APONVIE; we genuinely believe that APONVIE and the PONV market represent the next big opportunity at Heron. Let's begin with the name APONVIE signifies: aprepitant intended for PONV. Feedback from the brand-name market study was overwhelmingly favorable among healthcare providers and, crucially, sets apart this reduced-strength aprepitant emulsion formulation from CINVANTI, our very successful CINV offering. Our target will be 36 million procedures each year involving patients at moderate to high PONV risk; within that sizable group, roughly 12 million individuals facing moderate to high risk currently go without prophylaxis. A key objective of ours involves leveraging the 2020 consensus guidelines to shift that practice, expanding the market while tackling one of the biggest side-effect concerns for surgical patients. The market study surfaced several notable gaps in today's landscape, among them demand for a handier option with quicker action — something APONVIE delivers through a fast IV push plus 97 percent receptor occupancy inside 5 minutes. Providers also want greater efficacy, and for preventing PONV, whether used alone or alongside other agents, aprepitant stands as the most effective choice. Lastly, there's a need for longer duration of effect, and APONVIE supplies PONV prevention lasting as long as 48 hours. That final gap matters particularly given rising outpatient surgery volumes and patients going home just hours post-procedure. In brief, APONVIE stands out distinctly within this space and is set up to succeed. APONVIE additionally represents an ideal strategic match for Heron given the synergies with our commercial team. It begins with substantial account overlap among those we already pursue for ZYNRELEF. We hold established, trusted ties across anesthesia and pharmacy, which matters greatly for formulary access and uptake. Furthermore, roughly 65% of CINVANTI revenue originates in the hospital segment. Those prior favorable encounters at leading hospitals and IDNs ought to accelerate APONVIE access and adoption. Now, I'd like to discuss certain market study data involving healthcare providers together with how APONVIE pricing affects their share. The pie chart displays their general PONV prophylaxis usage for prevention segmented by patient risk level: low, moderate, and high. Predictably, the figure comes to 18% share among low-risk patients, climbing to 59% share among high-risk patients. The lower bar chart illustrates HCP market share at price points spanning $75 down to $35 per APONVIE vial. One notable takeaway was how share shifted across all 3 patient risk categories once pricing approached the $65 mark. Drawing on HCP input, we concluded WACC pricing in the $65 to $55 band was appropriate, yet formulary access for APONVIE also had to be weighed. Slide #20 offers essential market study insights from pharmacy directors regarding formulary access for APONVIE at price points spanning $40 to $96 per APONVIE vial. Again, a meaningful gap emerged between $65 and $55 WACC pricing when it came to formulary access for APONVIE, with $60 serving as the tipping point for access. Our aim was to choose an APONVIE pricing approach that delivers the greatest profit contribution to the company. When we settled on our final price recommendation, the goal was to strike a balance between HCP share in patients at moderate to high risk and the best possible formulary access, which includes how much usage of the product might be restricted. Taking all of that into account, APONVIE's launch price under WACC will be $58 per vial. Sales of APONVIE will be limited to end users, and it comes in packs of 10 vials. Beyond that, in line with how we price across the company, 340B pricing will be made available too, speeding up access for providers and patients; at a minimum discount of 23.1% off WACC, APONVIE under 340B will come in below $45 per vial. One thing worth flagging: market research demonstrated, and the 2 slides before this one back it up as well, that this lower price point yields additional HCP share and better formulary access. And last, as Barry noted, we remain on schedule to make APONVIE available in the first quarter of 2023. Let me now turn to something different and go over the third quarter results from our oncology care franchise. In that third quarter, our oncology care team performed exceptionally well, lifting net sales for our CINV portfolio by 13% compared with the same quarter a year earlier.
John Poyhonen
executiveBringing growth back to our CINV franchise after generic arbitrages involving both products is something we take great pride in, and we expect it to stay a valuable, highly profitable franchise for many years ahead; delivery of CINV net sales between $93 million and $95 million remains on track, which would mark an 11% to 14% rise versus prior year. Continued improving reimbursement tailwinds over the past year keep the outlook for our CINV products positive. The table below shows that versus the competition, both CINVANTI and SUSTOL sit in a far more favorable reimbursement position than at the same time last year, with generic fosaprepitant falling to $20.66 and IV Akynzeo falling to $423.12 reimbursement. On top of that, the removal of separate reimbursement for generic fosaprepitant in the hospital outpatient segment, effective January 1 of this year, keeps making the CINVANTI value proposition much more attractive. New CMS guidelines published in July stated that as of July 1 of 2023, reimbursement for 340B accounts will rise to ASP plus 6%, up from the earlier rate of ASP minus 22.5%; since the greatest portion of our CINV hospital demand units sit in 340B accounts, we believe this opportunity will help us grow sales units in the fourth quarter and in 2023. Lastly, large scale CINVANTI manufacturing is now online with product in the distribution channel, bringing significant improvements in our gross margin; that wraps up my prepared remarks, and I'll hand the call back over to Barry.
Barry Quart
executiveThanks, John. We're going to wrap up the formal portion with the slide covering our financials. As of September 30, 2022, Heron held $121.7 million in cash, cash equivalents and short-term investments. Operating activities consumed $37.1 million in net cash during the third quarter, which included restructuring costs tied to the workforce cut we made recently. The complete effect of cutting headcount by roughly 34% will keep flowing through this quarter and the one after. The remaining slides in the deck carry important safety information for ZYNRELEF and APONVIE. Those slides can be found on our website. That said, we're ready to take your questions. Dennis?
Brandon Folkes
analystI do appreciate the openness regarding how ZYNRELEF has been doing, yet it probably won't shock you that I'd like to press a bit further. Could you perhaps explain in more detail what shifted so dramatically from early August, when we had the 2Q call and guidance pointed toward roughly 40% to 50% growth quarter over quarter? By that point, July was already behind us, and we flagged that on today's call. In the same way, are there any visibility concerns around the October numbers you just referenced, given how July and August played out? Had you simply been counting on a stronger recovery in surgery? Any detail at all would help. Then, to tack on one more thing: Pacira did highlight better year-on-year trends in mid-August. Should we read anything into that remark alongside what you're reporting today?
Barry Quart
executiveYes. Thank you, Brandon. I'm glad you asked. And yes, I believe you've identified the core issue precisely; following a soft July, we had expected a far more pronounced bounce back, and clearly that is not what happened. On a month-to-month basis, it isn't always entirely obvious how much the macro conditions we're operating in are affecting things. You brought up the Pacira call. They had pointed to weakness heading into October. For us, October has looked exceptionally strong; so I suspect seasonality will differ between us and the products. Regarding the latter portion of the quarter and the reasons the rebound we expected never materialized, I'll let John provide any further details. I'd also mention that we carried out a restructuring that touched part of the commercial team; it has worked out quite well in terms of genuinely energizing that group. That said, with restructuring of any kind, there is inevitably some downtime while things get reorganized. So John, would you like to — anything to add?
John Poyhonen
executiveYeah. Barry, one more thing I'd mention — our outlook for Q4 feels really positive, and honestly, Brandon, the claims numbers and procedure patterns are beginning to back that up. So when we examine it, what we've typically tracked was a 5-week stretch compared with the 5 weeks before it for the procedures tied to the launch, and at last we're beginning to see that grow. That really showed up once Labor Day passed. September ended on a very strong note for us, and then we genuinely followed it up with our best month on record in October. And we're only 1 week in at this point, yet the first week of November is running above where October came in. So we're confident in what we've said about targeting 30% to 40% net sales growth for the quarter.
Brandon Folkes
analystThanks for that context. Perhaps just a quick item to add on. Earlier, you issued a projection regarding how long our cash would last. Clearly, when looking at growth from one quarter to the next, you're kind of well short, though not truly in terms of the amount measured in dollars. So I'd just like — could you simply tell us, following this ramp, are you still sticking with that cash runway figure? And then perhaps one further thing, if I can, in a somewhat more helpful spirit. Regarding the IDNs currently assessing ZYNRELEF in those trials, should you succeed in securing that additional label expansion, what's the right way for us to think about whether those IDNs would prefer to conduct another evaluation round? Or do you believe they'll simply incorporate it? Might they be testing it across a wider range of surgeries than the label covers? Any insight on that would be useful as well, when we consider the 2023 ramp.
Barry Quart
executiveThank you, Brandon. And in fact, I'm going to hand it to John to address the IDN question first, and after that I'll cover the cash runway.
John Poyhonen
executiveYes, that's an excellent question, Brandon. And our view is that, unfortunately, this is going to vary from one IDN to the next. There are some accounts where they've already reached the stage of removing Exparel from formulary; and in those accounts, we believe the extra indicated procedures we're set to gain will let us capture a big chunk of that business fairly fast; with others, it could take somewhat longer. So it's a little early to make that determination. But I'd say we're pleased that in certain accounts, the results they're seeing are so strong. One that stands out comes to mind: it has 6 different hospitals inside the IDN, and 3 of those have already taken Exparel off formulary; and results like that are what get us excited. Our aim isn't to have Exparel removed or to increase usage. But in those cases where Exparel isn't there as a branded competitor, we believe that business can expand far more quickly with the additional label expansion.
Barry Quart
executiveThanks, John. Sure, regarding our cash runway — clearly, how long that runway lasts depends on our burn rate and the revenue we bring in. We're putting a lot of effort into growing revenue, as John walked everyone through during his presentation, and we're also examining options to keep the burn in check, obviously. When we first issued guidance, we expected the burn to rise during this quarter. We were in the process of completing validations for large scale manufacturing of ZYNRELEF as well as CINVANTI, and that work requires extra resources. That was built into the plan from the start. So we're doing whatever we can to hold to that guidance.
Josh Schimmer
analystFirst question, I suppose — for 2023 or 2024, should we anticipate that APONVIE's revenue will come in above ZYNRELEF's?
Barry Quart
executiveHonestly, providing revenue guidance at this point feels a bit premature. Unit volumes, I'd say, definitely have the potential to run higher. When it comes to dollar revenue, that would be a tough goal to hit. John, is there anything else — any further perspective you'd add on that?
John Poyhonen
executiveNo, I think that's well stated, Barry. I don't have anything to add.
Josh Schimmer
analystAll right. And you still haven't given us a real, clear reason why the ZYNRELEF launch has fallen this far short of what was expected; and that makes it pretty difficult to feel much confidence in some of what you're saying and in your optimism that you'll be able to get things back on track when you can't actually explain how things went so wrong in the first place. So could you perhaps walk through the top 3 or 4 factors where you think we missed relative to the launch and the original expectations, and how you plan to put those right?
Barry Quart
executiveWell, absolutely. I'll kick things off and John can wrap up. As you're aware, Josh, the initial label we received for ZYNRELEF was less than ideal, and it wound up affecting utilization far more than the early market research had suggested it would. And I believe you've noted yourself that this was plainly a miss on our side, that we ought to have recognized it would matter more. We dropped the ball when it came to trusting the market research, when it came to the idea that surgeons didn't much care what the indication statement said. And of course, that was a sensible position to take, considering how our competitors' product gets used off-label in the nerve block space. So it looked sensible. It simply didn't prove to be true. We were lucky enough to have the label revised in December. That has assisted in growing utilization and has assisted in bringing on these therapeutic interchanges from IDNs. We remain somewhat constrained by the label, which is still diminished. What that means is certain IDNs won't consider a therapeutic interchange since the range of indications isn't wide enough; so obviously we still have efforts underway, as has already been mentioned, to resolve that problem, and we expect it to be fixed in the second half of next year. The other difficulty we've recognized is that getting a surgeon comfortable with the product, and getting the staff comfortable with the product, takes more sales rep time per surgeon. And given the far greater turnover among staff than we ever expected before COVID, or even once COVID began to fade, we failed to recognize the turnover problems hospitals would face with staff. It simply takes more rep time for each individual surgeon. And that has clearly meant sales reps reaching fewer new surgeons and not growing utilization as fast as we had definitely projected. John, is there anything else you'd like to add?
John Poyhonen
executiveAbsolutely, Barry. In my view, the two things you just mentioned mattered a great deal. Beyond those, another major factor we've run into is this: practically every account appears to be carrying out its own separate assessment of ZYNRELEF. So despite having those excellent, tightly controlled trials versus bupivacaine, the existing standard of care, and coming out ahead, accounts continue to run their own tests on the product. When we ask why, the answer comes through unmistakably. Exparel claimed 72 hours to us, and that claim doesn't hold up. The actual duration is 24 to 30 hours. So now, with ZYNRELEF, we have to demonstrate that you genuinely get 72 hours. Because of that, having to work through this kind of assessment at each individual account, frequently across several procedures — meaning you may need to engage an orthopedic surgeon plus a soft tissue specialist — has consumed much more time than we ever anticipated. That's among the reasons we're eager to confirm we've got the appropriate resources in place through the flexible resource deployment as we move ahead, Josh.
Barry Quart
executiveRight, I'd simply add this: we definitely understood some hospital trials would happen, for the reasons John laid out. However, how large and extensive these trials turned out to be, plus how long they've taken, is far beyond what we'd anticipated. The results we're seeing are excellent, and the feedback coming in is definitely positive. It's simply an extremely time-intensive procedure, and it has held back the product's launch.
Serge Belanger
analystLet's begin with a few short questions regarding ZYNRELEF. During Q3, it appears net price shifts created somewhat of a drag. I'm just wondering whether you anticipate further net price changes over the next several quarters. Then second, could you perhaps discuss the market share you hold within the procedure you target and indicate? We're just attempting to also understand where you might be taking business from Exparel. And last, I believe John brought up adding more resources during Q4 in order to re-energize ZYNRELEF. I'm curious how that impacts OpEx, and exactly how many extra personnel are involved here?
Barry Quart
executiveJohn, would you like to address that?
John Poyhonen
executiveRight, so what you're saying is accurate, Serge — net price definitely took a hit. With the broader label we got back in December, the SKU mix has shifted somewhat. During the first 6 months, it was roughly 80% 400 milligram versus 200% — sorry, 20% 200 milligram. In the most recent quarter, that split was around 67% for the 400 and 33%. Simply because of that SKU change, your net price comes out lower. Combine that with the expansion we've had in 340B accounts — those accounts rose roughly 25% between the second and third quarter — and you're looking at a reduced net price. So from a modeling standpoint, I'd suggest revising that downward, since we've moved toward a greater share of the 200 milligram SKU, to a model price of roughly $1.75 to $1.80 for net price per unit. As for where we're taking share from Exparel, I mentioned earlier this idea of branded market share, which measures ZYNRELEF units as a percentage of the combined Exparel and ZYNRELEF units. Looking at the total market that way, ZYNRELEF currently sits at a share of roughly 3.8%. When you set that against the figures we report for the IDNs, you'll notice the IDNs — even across the 66 IDNs — show 8.1% and 12.4%; so growth there is genuinely strong relative to the broader market, which is among the reasons we'll keep concentrating on those IDNs, particularly the ones running therapeutic interchanges. And I believe your final question concerned how this ties to OpEx given these flexible resources. What I'd note is that all of this is contracted work performed for us. So these aren't company employees, so to speak. Some are full-time operating room educators able to travel wherever the business is. They function as a HIT, or hospital implementation team, helping us stand up an IDN very quickly. The rest are part-time, local, flexible support. That group covers OR nurses along with other support staff; we also deploy them for in-services and to build relationships with surgeons. We're also working with certain medical device reps. The crucial distinction in our approach versus what other companies have tried is that payment only happens if they were actually present in a ZYNRELEF case — if they're in the operating room supporting its in-service. It's really a completely different approach, and bit by bit it definitely returns more than it costs. That said, as Barry noted, we did see some trimming that we examined within the commercial side of the business, and we can definitely more than counterbalance those modest added expenses as we run trial pilots with some of these new flexible resources — including a $175 figure and a $180 figure tied to that effort, alongside a 433% return. So I'm not sure whether you'd like to add anything there, Barry.
Barry Quart
executiveNo, I believe your explanation was thorough. Honestly, the added expense for those contract workers is basically being absorbed by the commercial budget we already had. When it comes to burn, there won't be a major effect. As I mentioned earlier, keeping burn under control is clearly a big priority for us. Still, I think it's worth repeating that the efforts John described, which are only at an early point, are showing us obvious signs that they're working — in terms of pull-through, in terms of getting IDNs to move faster on the therapeutic interchanges; and we're seeing that reflected in weekly sales gains. And I'll add that, like I said before, when it comes to bringing on extra field reps and doing co-promote style work, this is a page out of the Exparel playbook from when they first launched. It made a real difference to how their launch trajectories played out; so I think this is something we may be a bit late in the game in implementing, but it's clearly making an important impact; and we're very confident that these efforts are bearing fruit and will keep doing so when it comes to hitting the target growth we've identified for fourth quarter.
Serge Belanger
analystOne final item, and then we're done. I'm wondering whether the oncology franchise, at the sales guidance of $93 million to $95 million, turns a profit for the company and <<inaudible>>
John Poyhonen
executiveSerge, I don't think we heard how your question ended. That said, yes, this is a highly profitable franchise at present. So I can't tell whether you wanted additional detail.
Serge Belanger
analystWhat sorts of reimbursement shifts might fuel extra growth in 2023?
Barry Quart
executiveYeah, John described a driver we consider quite significant. And it's largely quite comparable to a key driver for ZYNRELEF regarding how CINVANTI and SUSTOL get reimbursed, actually, within the hospital context, where following a recent Supreme Court ruling, CMS is going to revert to paying 340B hospitals the complete ASP plus 6% instead of minus 22.3%. That represents an enormous windfall when you've got a product such as CINVANTI where they could earn, let's say, $40, while fosaprepitant gets no reimbursement whatsoever since it has dropped beneath the reimbursement threshold. Consequently, many 340B hospitals that switched to generic fosaprepitant to exploit that arbitrage are now either returning or weighing a return to CINVANTI. And that's definitely going to be a major driver for us as we head into next year.
John Poyhonen
executiveSure. I can add a bit more detail there, Barry. With this fresh reimbursement boost for 340B hospitals, those IDNs that switched over to generic fosaprepitant to take advantage of the arbitrage — we have already signed contracts with 3 IDNs to bring them back to CINVANTI. Since a number of these IDNs each run over 30 hospitals, bringing them back and getting them using the product takes some time. Still, we feel quite optimistic about how this quarter might shape up, and as we move into next year, we believe that could help drive growth. We also keep talking with other IDNs that previously used CINVANTI, and that conversation works perfectly since we will be out there speaking with them about APONVIE too.
Barry Quart
executiveYes, and I would mention as well that our ability to supply CINVANTI has been rather limited, honestly, right through this quarter, since the quantities we could produce were small; because of that, we deliberately moved slowly on some opportunities that might have existed, simply due to how little material was available to make, despite having 2 contract manufacturers. As was mentioned earlier, we have by now validated manufacturing at a larger scale — a 10x increase — and that lets us significantly broaden availability. We've also gone full throttle when it comes to pursuing new business again, and we will keep doing that.
Barry Quart
executiveAbsolutely, and I appreciate all of you being here with us today on this call. As was mentioned, it's clear we're quite unhappy about how ZYNRELEF performed in Q3, yet we remain highly encouraged regarding Q4 and what comes after. We're seeing that establishing the foundation of the business that John described during the call is beginning to pay off. Plus, with certain new programs we've implemented and the rise in procedures, we feel very good about Q4 and as we head into next year. So thanks so much for listening in, and we're eager to bring you further updates down the road.
Operator
operatorEveryone, we've reached the end of today's conference call. We appreciate you joining us. You're free to hang up now. Farewell.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Heron Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.